SAM Chun Dang Pharm삼천당제약
000250 · KOSDAQ · ₩000250 · 삼천당제약
₩190,000▲ ₩2,400 (1.28%)End-of-day · Oct 28, 2026 · End-of-day prices.
Filings
- 5%+ holding report주식등의대량보유상황보고서(일반)Oct 20, 2026Open on DART
Predicted impact: Low
- Amended: Half-year report (Jun 2026)[기재정정]반기보고서 (2026.06)Oct 8, 2026Open on DART
- Amended: Quarterly report (Mar 2026)[기재정정]분기보고서 (2026.03)Oct 8, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 캐나다 독점판매권 공급계약 체결 및 중동 6개 국가 추가 계약 체결)Oct 1, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Aug 14, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)Aug 5, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)Aug 5, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Jul 23, 2026Open on DART
- Results of Extraordinary Shareholders' Meeting임시주주총회결과Jun 30, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Jun 30, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Jun 12, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Jun 10, 2026Open on DART
- Amended: Annual report (Dec 2025)[기재정정]사업보고서 (2025.12)Jun 4, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)May 29, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Apr 27, 2026Open on DART
- Shareholders' meeting called주주총회소집결의 (임시주주총회)Apr 27, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Apr 27, 2026Open on DART
- Designation as Unfaithful Disclosure Company (Failure to Disclose)불성실공시법인지정 (공시불이행)Apr 20, 2026Open on DART
- Amended: Investor relations (IR) event[기재정정]기업설명회(IR)개최Apr 16, 2026Open on DART
- Withdrawal of Trading Plan Report for Executives and Major Shareholders' Specific Securities임원ㆍ주요주주특정증권등거래계획철회보고서Apr 6, 2026Open on DART
- Notice of Planned Designation as Unfaithful Disclosure Company (Failure to Disclose)불성실공시법인지정예고 (공시불이행)Mar 31, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 30, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (경구용 당뇨 치료제 리벨서스 제네릭 및 경구용 비만 치료제 위고비 오럴 제네릭(세마글루타이드) 미국 라이센스 계약 체결)Mar 30, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 30, 2026Open on DART
- Trading Plan Report for Executives and Major Shareholders' Specific Securities임원ㆍ주요주주특정증권등거래계획보고서Mar 24, 2026Open on DART
- Audit report submitted감사보고서제출Mar 20, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Mar 20, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 20, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)Mar 19, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 10, 2026Open on DART
- Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 3, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 3, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (경구용 당뇨 치료제 리벨서스 제네릭 및 경구용 비만 치료제 위고비 오럴 제네릭(세마글루타이드) 영국 외 유럽 10개 국가 독점 라이센스 및 상업화 계약 체결)Feb 26, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 캐나다 독점판매권 공급계약 체결 및 중동 6개 국가 추가 계약 체결)Feb 19, 2026Open on DART
- Cash dividend decision현금ㆍ현물배당결정Feb 10, 2026Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 10, 2026Open on DART
- Material Disclosure Obligation-Related Matters (Fair Disclosure) (Entry into Joint Development and Commercialization Partnership Agreement for Oral Semaglutide for Sale in Japan)수시공시의무관련사항(공정공시) (일본 판매용 경구용 세마글루타이드 공동개발 및 상업화 파트너십 계약 체결)Jan 22, 2026Open on DART
- Amended: Major sales or supply contract[기재정정]단일판매ㆍ공급계약체결(자율공시)Dec 29, 2025Open on DART
- Amended: Major sales or supply contract[기재정정]단일판매ㆍ공급계약체결(자율공시)Dec 24, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2025Open on DART
- Shareholder Register Closure for Cash/Stock Dividend (Record Date) Decision현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정Dec 16, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Dec 9, 2025Open on DART
- Amended: Major sales or supply contract[기재정정]단일판매ㆍ공급계약체결(자율공시)Nov 28, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411 2mg 저용량(Vial&PFS) 및 8mg 고용량(Vial&PFS)의 미국 및 라틴아메리카 6개국 독점 공급 및 판매계약 체결)Nov 12, 2025Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Oct 24, 2025Open on DART
- Acquisition of shares in another company타법인주식및출자증권취득결정(자율공시)Oct 22, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (황반변성치료제(아일리아/주성분 : Aflibercept) 바이오시밀러 SCD411(Vial&PFS)의 동유럽 8개국(폴란드, 체코, 슬로바키아, 헝가리, 리투아니아, 라트비아, 에스토니아, 루마니아) 독점판매권 및 공급계약 체결)Sep 22, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: SAM Chun Dang Pharm / 삼천당제약 / 000250 / KRX:000250
Source: KRX statistical information